Serial Assessment of Immune Status by Circulating CD8+ Effector T Cell Frequencies for Posttransplant Infectious Complications
Table 1
Hierarchical clustering in 3 Groups.
(a)
Group
Age (y)
% Naive
% CM
% EM
% Effector
% Lymphocytes*
% CD4†
% CD8†
T cells
T cells
T cells
T cells
I
31
II
33
III
28
(b)
Variance
All
.0501
<.0001
<.0001
<.0001
<.0001
.8693
.4087
.6845
I versus II
.0223
<.0001
.0016
<.0001
.0089
.5910
.9567
.6480
I versus III
.0647
<.0001
.1001
.9287
<.0001
.7446
.2681
.7004
II versus III
.9133
.8840
<.0001
<.0001
<.0001
.8735
.2066
.3534
(c)
Group I
Group II
Group III
Recipient (male/female)
31 (18/13)
33 (23/10)
28 (15/13)
.4049‡
Original liver disease
—
—
—
.1456‡
Nonviral
14
9
6
—
HBV
6
12
6
—
HCV
11
13
16
—
MELD
.5460§
HLA mismatch (0–2/>3)
17/13
16/15
7/21
.0347‡
CMV status: R+ (D+/R−)
26/29 (3/29)
25/31 (6/31)
23/26 (2/26)
.5504 (0.3971)‡
EBV status: R+ (D+/R−)
24/29 (3/29)
28/30 (2/30)
23/27 (3/27)
.4442 (0.8232)‡
Operation profile
GWBR
.4422§
Ischemic time (min)
Cold
.1276§
Warm
.5502§
Blood loss (g)
.8615§
Blood loss/BW
.8719§
Viral status: R+; recipient with preoperative positive serology, D+/R−; donor-positive and recipient-negative status, *% of peripheral blood mononuclear cells; †% of lymphocytes; ‡Categorical variables were compared using Fisher’s exact test or chi-squared test; §Continuous variables between groups were compared using Student’s t-test or ANOVA. Values are expressed as mean ±SD.
